|
|
|
|
|
|
|
30.03.26 - 22:12
|
John B. Sanfilippo & Son, Inc. Declares $1.50 Per Share Special Dividend (Business Wire)
|
|
|
ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced that its Board of Directors (the “Board”) declared a special cash dividend (the “Special Dividend”) of $1.50 per share on all issued and outstanding shares of Common Stock of the Company and $1.50 per share on all issued and outstanding shares of Class A Common Stock of the Company. The Special Dividend will return approximately $17.6 million to Company stockholders.
The Special Dividend will be paid on May 21, 2026, to stockholders of record as of the close of business on April 27, 2026.
“We are pleased to announce the $1.50 per share Special Dividend,” stated Jeffrey T. Sanfilippo, Chairman and Chief Executive Officer. “Our financial performance over the last several quarters has enabled us to declare another Special Dividend in the current fiscal year. This Special Dividend, along with the special dividends and annual dividend previously paid by the Company, brings the total cas...
|
|
|
09.03.26 - 12:12
|
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates (Business Wire)
|
|
|
Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026
Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT
Secured up to $50 Million in Growth Capital from Avenue Capital GroupSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates.
“2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement therapy (TA-ERT) program, especially our planned biologics license application (BLA) submission in the fourth quarter of this y...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.01.26 - 22:15
|
John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Second Quarter Results (Business Wire)
|
|
|
Record Breaking Net Sales Drove a Diluted EPS Increase of 31.9% to $1.53 per Share ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced financial results for its fiscal 2026 second quarter ended December 25, 2025.
Second Quarter Summary
Net sales increased $13.7 million, or 4.6%, to $314.8 million
Sales volume decreased 9.3 million pounds, or 9.7%, to 87.0 million pounds
Gross profit increased 13.2% to $59.2 million
Diluted EPS increased 31.9% to $1.53 per share
CEO Commentary
“We delivered strong top-line growth and achieved an approximately 32% increase in diluted earnings per share for the quarter, driven by executing our ongoing strategic initiatives of disciplined cost management, operational efficiencies and strategic pricing actions. While these results are encouraging, we continue to navigate headwinds from shifting consumer behavior, emerging health and wellness trends and elevated retail selling prices, which weighed on overall sales v...
|
|
|
|
|
|
|
22.01.26 - 22:24
|
John B. Sanfilippo & Son, Inc. 2nd Quarter Fiscal Year 2026 Operating Results Conference Call (Business Wire)
|
|
|
ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its second quarter Fiscal 2026 operating results on Friday, January 30, 2026 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Second Quarter Results are expected to be released after the market closes on Thursday January 29, 2026.
To register for the call, please click on the Participant Registration by register using this link: Conference Registration
After registering, an email will be sent, including dial-in details and a unique access code required to join the live call. Please ensure you have registered at least 15 minutes prior to the conference call time.
This call is being webcast by Notified and can be accessed at John B. Sanfilippo & Son, Inc.'s Web site at www.jbssinc.com.
Based in Elgin, Illinois, John B. Sanfilippo & Son, Inc. is a processor, packager, marketer and dis...
|
|
|
15.12.25 - 14:09
|
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors (Business Wire)
|
|
|
Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors.
“Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB),” said Michael Grey, Executive Chairman of Spruce Biosciences. “Her experience in successfully launching multiple drugs and her deep understanding of the rare disease commercial landscape will help support our transition into a commercial-stage organization focused on delivering potentially the first disease-modifying therapy for children with MPS IIIB.”
Ms. Walbert...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
